ArticleFrontiers in oncology2025
SPINK1 facilitates tumor progression via the EGFR/JAK/STAT3 axis in oral squamous cell carcinoma: insights from single-cell RNA sequencing.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic Profiling of Toxic Copper Overload Induced by CuO Nanoparticles or Copper Ions in Human Lung Epithelial and Liver Cells.Nanomaterials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to elucidate the functional role and molecular mechanisms of Serine Peptidase Inhibitor Kazal Type 1 (SPINK1) in oral squamous cell carcinoma (OSCC) through integrative analysis of single-cell RNA sequencing (scRNA-seq) data. Materials and methods: Cellular subpopulations within OSCC were stratified using transcriptomic datasets from the GEO database. Cell-cell communication networks were reconstructed to map ligand-receptor interactions, while Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) were employed to systematically investigate SPINK1-associated signaling pathways. SPINK1 expression profiles in OSCC tissues were validated through quantitative PCR (qPCR) and immunoblotting. Gain- and loss-of-function assays utilizing Cell Counting Kit-8 (CCK-8), wound healing assays, transwell migration/invasion chambers, and murine xenograft models were implemented to assess SPINK1-mediated oncogenic phenotypes. Rescue experiments conclusively established the EGFR/JAK/STAT3 signaling axis as the mechanistic backbone of SPINK1-driven oncogenesis. Results: SPINK1 was closely associated with T cells, malignant cells, and an array of immune modulators, including chemokines and immunoinhibitors, throughout OSCC progression. SPINK1 operates through pathways involving JAK/STAT3, P53, Notch and WNT signaling cascades. Relative to their normal tissue counterparts, SPINK1 is upregulated in OSCC, resulting in increased cell proliferation, invasion, and migration upon SPINK1 overexpression, whereas SPINK1 knockdown has opposite effects. SPINK1 knockdown led to a significant reduction in EGFR and STAT3 phosphorylation levels, whereas exogenous supplementation of EGFR effectively rescued this phenotype. Conclusion: SPINK1 has been established as a novel therapeutic target in OSCC, with its dual role in tumorigenesis and immune modulation providing a molecular foundation for developing targeted therapeutic modalities and precision oncology strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.